Cloned Polo Horses Scale via Industrial Breeding Operations

Polo teams in Argentina and the US now deploy cloned replicas of elite horses at rates exceeding 20% of mounts in high-goal matches, according to 2026 reporting on Santa Fe and Buenos Aires facilities. Primary data from embryo transfer records show Viagen and Crestview Genetics producing over 100 clones annually since 2018, with lineages tracing to 2003 mules and 2005 horses. Related equine studies document 95% genetic identity in nuclear transfer outcomes, confirming performance parity in speed and endurance metrics. Regulatory filings from the International Polo Federation omit clone disclosure rules, leaving gaps that mirror 2010s Thoroughbred cloning bans. Argentine export logs tie operations to private equity ownership of string stables, concentrating genetic assets among teams with $5M+ annual budgets. A 2022 Theriogenology review cross-references 150 equine clones, noting zero enforcement of welfare audits despite documented late-gestation losses. Patterns from 2015-2024 show repeat cloning of the same donor lines, amplifying heritability of traits like agility without corresponding data on long-term musculoskeletal outcomes.